New Guidelines Recommend Medications for Weight Loss to Prevent Heart Disease in US
PorAinvest
viernes, 20 de junio de 2025, 10:58 am ET1 min de lectura
GDRX--
The study highlights the growing demand for effective weight management solutions. According to GoodRx data, the number of patients receiving Wegovy has doubled, while those receiving Zepbound have tripled since January 2024 [2]. Despite the high costs and limited insurance coverage, Americans are increasingly seeking these medications to manage their weight and improve their overall health.
HealthRX, a U.S.-based digital health platform, has recently expanded its online experience to include access to GLP-1 medications such as Ozempic, Zepbound, and compounded alternatives [1]. The platform offers a streamlined process for adults to explore medically appropriate weight loss options from the comfort of their homes. HealthRX facilitates access to these medications through a three-step intake process, which includes a clinical questionnaire, virtual consultation with a board-certified physician, and secure prescription delivery.
The platform emphasizes convenience and flexibility, removing the need for in-person consultations or insurance requirements. HealthRX also offers a suite of wellness support tools, including coaching support, educational resources, medication reminders, and outcome tracking, to reinforce adherence and increase long-term success [1].
The study by the ACC aims to influence insurance companies and federal programs to cover these medications, making them more accessible to a broader range of patients. The study suggests that increasing access to these treatments could significantly impact the number of heart disease cases and deaths in the United States.
References:
[1] https://www.globenewswire.com/news-release/2025/06/20/3102506/0/en/HealthRX-Expands-Telehealth-Website-Experience-to-Include-GLP-1-Weight-Loss-Solutions-Prescription-Access-and-24-7-Wellness-Support.html
[2] https://qz.com/ozempic-wegovy-zepbound-grail-1851714968
GLP--
RXRX--
A new study by the American College of Cardiology recommends that millions of Americans take weight-loss medications to prevent heart disease. The study suggests that exercise and healthy diet alone may not be enough to maintain heart health. Medications like Wegovy and Zepbound should be considered primary treatments for preventing heart disease, which is the leading cause of death in the US. The study aims to improve access to these treatments by influencing insurance companies and federal programs to cover them.
A recent study by the American College of Cardiology (ACC) has sparked significant interest in the use of weight-loss medications to prevent heart disease. The study, published in the journal JAMA Network Open, recommends that millions of Americans consider taking medications such as Wegovy and Zepbound as primary treatments to maintain heart health. The study suggests that while exercise and a healthy diet are essential, they may not be sufficient on their own to prevent heart disease, which remains the leading cause of death in the United States [2].The study highlights the growing demand for effective weight management solutions. According to GoodRx data, the number of patients receiving Wegovy has doubled, while those receiving Zepbound have tripled since January 2024 [2]. Despite the high costs and limited insurance coverage, Americans are increasingly seeking these medications to manage their weight and improve their overall health.
HealthRX, a U.S.-based digital health platform, has recently expanded its online experience to include access to GLP-1 medications such as Ozempic, Zepbound, and compounded alternatives [1]. The platform offers a streamlined process for adults to explore medically appropriate weight loss options from the comfort of their homes. HealthRX facilitates access to these medications through a three-step intake process, which includes a clinical questionnaire, virtual consultation with a board-certified physician, and secure prescription delivery.
The platform emphasizes convenience and flexibility, removing the need for in-person consultations or insurance requirements. HealthRX also offers a suite of wellness support tools, including coaching support, educational resources, medication reminders, and outcome tracking, to reinforce adherence and increase long-term success [1].
The study by the ACC aims to influence insurance companies and federal programs to cover these medications, making them more accessible to a broader range of patients. The study suggests that increasing access to these treatments could significantly impact the number of heart disease cases and deaths in the United States.
References:
[1] https://www.globenewswire.com/news-release/2025/06/20/3102506/0/en/HealthRX-Expands-Telehealth-Website-Experience-to-Include-GLP-1-Weight-Loss-Solutions-Prescription-Access-and-24-7-Wellness-Support.html
[2] https://qz.com/ozempic-wegovy-zepbound-grail-1851714968

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios